Correlating familial Alzheimer’s disease gene mutations with clinical phenotype

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Rossor MN, Newman S, Frackowiak RS, Lantos P, Kennedy AM: Alzheimer’s disease families with amyloid precursor protein mutations. Ann. NY Acad. Sci.695,198–202 (1993).
  Medline CASGoogle Scholar
• 2  Goate A, Chartier-Harlin MC, Mullan M et al.: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature349(6311),704–706 (1991).
  Medline CASGoogle Scholar
• 3  Sherrington R, Rogaev EI, Liang Y et al.: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature375(6534),754–760 (1995).
  Medline CASGoogle Scholar
• 4  Levy-Lahad E, Wasco W, Poorkaj P et al.: Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science269(5226),973–977 (1995).
  Medline CASGoogle Scholar
• 5  Rovelet-Lecrux A, Hannequin D, Raux G et al.: APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet.38(1),24–26 (2006).▪ Duplication of the amyloid precursor protein locus was found to be a cause of autosomal dominantly inherited early-onset Alzheimer’s disease (AD), with prominent amyloid angiopathy.
  Medline CASGoogle Scholar
• 6  Larner AJ, Doran M: Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1gene. J. Neurol.253(2),139–158 (2006).▪ Comprehensive review of the various atypical features reported in association with PSEN1 mutations.
  Medline CASGoogle Scholar
• 7  Larner AJ, Doran M: Genotype–phenotype relationships of presenilin-1 mutations in Alzheimer’s disease: an update. J. Alzheimers Dis.17(2),259–265 (2009).▪ A further review of the clinical phenomenology of PSEN1 mutations, including some more recently published studies.
  Medline CASGoogle Scholar
• 8  Selkoe DJ: Alzheimer’s disease: genotypes, phenotypes, and treatments. Science275(5300),630–631 (1997).
  Medline CASGoogle Scholar
• 9  Nilsberth C, Westlind-Danielsson A, Eckman CB et al.: The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Aβ protofibril formation. Nat. Neurosci.4(9),887–893 (2001).
  Medline CASGoogle Scholar
• 10  Holmes C: Genotype and phenotype in Alzheimer’s disease. Br. J. Psychiatry180,131–134 (2002).
  MedlineGoogle Scholar
• 11  Godbolt AK, Cipolotti L, Watt H, Fox NC, Janssen JC, Rossor MN: The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort. Arch. Neurol.61(11),1743–1748 (2004).
  MedlineGoogle Scholar
• 12  Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T: Amyloid angiopathy and variability in amyloid β deposition is determined by mutation position in presenilin-1-linked Alzheimer’s disease. Am. J. Pathol.158(6),2165–2175 (2001).▪ The histopathological profile in PSEN1 mutations appears to be driven by the position of the mutation in the gene, with more severe amyloid angiopathy observed in mutations beyond codon 200.
  Medline CASGoogle Scholar
• 13  Van Broeckhoven C, Backhovens H, Cruts M et al.: APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer’s disease. Neurosci. Lett.169(1–2),179–180 (1994).
  Medline CASGoogle Scholar
• 14  Pastor P, Roe CM, Villegas A et al.: Apolipoprotein Ee4 modifies Alzheimer’s disease onset in an E280A PS1 kindred. Ann. Neurol.54(2),163–169 (2003).
  Medline CASGoogle Scholar
• 15  Fox NC, Warrington EK, Seiffer AL, Agnew SK, Rossor MN: Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer’s disease. A longitudinal prospective study. Brain121(Pt 9),1631–1639 (1998).▪ Neuropsychological deficits, manifested in a decrease in performance IQ and verbal memory scores, are detectable several years prior to symptoms onset in familial AD mutation carriers.
  MedlineGoogle Scholar
• 16  Warrington EK, Agnew SK, Kennedy AM, Rossor MN: Neuropsychological profiles of familial Alzheimer’s disease associated with mutations in the presenilin 1 and amyloid precursor protein genes. J. Neurol.248(1),45–50 (2001).
  Medline CASGoogle Scholar
• 17  Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC: Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI. Proc. Natl Acad. Sci. USA99(7),4703–4707 (2002).▪ Global brain atrophy increases with advancing disease in familial AD, and regional hippocampal atrophy is already occurring prior to the onset of symptoms.
  Medline CASGoogle Scholar
• 18  Chan D, Janssen JC, Whitwell JL et al.: Change in rates of cerebral atrophy over time in early-onset Alzheimer’s disease: longitudinal MRI study. Lancet362(9390),1121–1122 (2003).
  MedlineGoogle Scholar
• 19  Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild-cognitive impairment: clinical characterization and outcome. Arch. Neurol.56(3),303–308 (1999).
  Medline CASGoogle Scholar
• 20  Godbolt AK, Beck JA, Collinge J et al.: A presenilin 1 R278I mutation presenting with language impairment. Neurology63(9),1702–1704 (2004).
  Medline CASGoogle Scholar
• 21  Gorno-Tempini ML, Brambati SM, Ginex V et al.: The logopenic/phonological variant of primary progressive aphasia. Neurology71(16),1227–1234 (2008).
  Medline CASGoogle Scholar
• 22  Marcon G, Di Fede G, Giaccone G et al.: A novel Italian presenilin 2 gene mutation with prevalent behavioral phenotype. J. Alzheimers Dis.16(3),509–511 (2009).
  Medline CASGoogle Scholar
• 23  Queralt R, Ezquerra M, Lleo A et al.: A novel mutation (V89L) in the presenilin 1 gene in a family with early-onset Alzheimer’s disease and marked behavioural disturbances. J. Neurol. Neurosurg. Psychiatr.72(2),266–269 (2002).
  Medline CASGoogle Scholar
• 24  Zekanowski C, Golan MP, Krzysko KA et al.: Two novel presenilin 1 gene mutations connected with frontotemporal dementia-like clinical phenotype: genetic and bioinformatic assessment. Exp. Neurol.200(1),82–88 (2006).
  Medline CASGoogle Scholar
• 25  Rippon GA, Crook R, Baker M et al.: Presenilin 1 mutation in an African American family presenting with atypical Alzheimer dementia. Arch. Neurol.60(6),884–888 (2003).
  MedlineGoogle Scholar
• 26  Raux G, Gantier R, Thomas-Anterion C et al.: Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology55(10),1577–1578 (2000).
  Medline CASGoogle Scholar
• 27  Amtul Z, Lewis PA, Piper S et al.: A presenilin 1 mutation associated with familial frontotemporal dementia inhibits γ-secretase cleavage of APP and notch. Neurobiol. Dis.9(2),269–273 (2002).
  Medline CASGoogle Scholar
• 28  Tang-Wai D, Lewis P, Boeve B et al.: Familial frontotemporal dementia associated with a novel presenilin-1 mutation. Dement. Geriatr. Cogn. Disord.14(1),13–21 (2002).
  Medline CASGoogle Scholar
• 29  Pickering-Brown SM, Baker M, Gass J et al.: Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain129(Pt 11),3124–3126 (2006).
  MedlineGoogle Scholar
• 30  Mendez MF, Ghajarania M, Perryman KM: Posterior cortical atrophy: clinical characteristics and differences compared with Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.14(1),33–40 (2002).
  MedlineGoogle Scholar
• 31  Snider BJ, Norton J, Coats MA et al.: Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch. Neurol.62(12),1821–1830 (2005).
  MedlineGoogle Scholar
• 32  Kennedy AM, Newman S, McCaddon A et al.: Familial Alzheimer’s disease. A pedigree with a mis-sense mutation in the amyloid precursor protein gene (amyloid precursor protein 717 valine–>glycine). Brain116(Pt 2),309–324 (1993).
  MedlineGoogle Scholar
• 33  Campion D, Brice A, Dumanchin C et al.: A novel presenilin 1 mutation resulting in familial Alzheimer’s disease with an onset age of 29 years. Neuroreport7(10),1582–1584 (1996).
  Medline CASGoogle Scholar
• 34  Karlstrom H, Brooks WS, Kwok JB et al.: Variable phenotype of Alzheimer’s disease with spastic paraparesis. J. Neurochem.104(3),573–583 (2008).▪ Detailed review of the association between AD and spastic paraparesis.
  Medline CASGoogle Scholar
• 35  Assini A, Terreni L, Borghi R et al.: Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation. Neurology60(1),150- (2003).
  Medline CASGoogle Scholar
• 36  Hiltunen M, Helisalmi S, Mannermaa A et al.: Identification of a novel 4.6-kb genomic deletion in presenilin-1 gene which results in exclusion of exon 9 in a Finnish early-onset Alzheimer’s disease family: an Alu core sequence-stimulated recombination?. Eur. J. Hum. Genet.8(4),259–266 (2000).
  Medline CASGoogle Scholar
• 37  Verkkoniemi A, Somer M, Rinne JO et al.: Variant Alzheimer’s disease with spastic paraparesis: clinical characterization. Neurology54(5),1103–1109 (2000).
  Medline CASGoogle Scholar
• 38  O’Riordan S, McMonagle P, Janssen JC et al.: Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology59(7),1108–1110 (2002).
  MedlineGoogle Scholar
• 39  Houlden H, Baker M, McGowan E et al.: Variant Alzheimer’s disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-β concentrations. Ann. Neurol.48(5),806–808 (2000).
  Medline CASGoogle Scholar
• 40  Tabira T, Chui DH, Nakayama H, Kuroda S, Shibuya M: Alzheimer’s disease with spastic paresis and cotton wool type plaques. J. Neurosci. Res.70(3),367–372 (2002).
  Medline CASGoogle Scholar
• 41  Yokota O, Terada S, Ishizu H et al.: Variability and heterogeneity in Alzheimer’s disease with cotton wool plaques: a clinicopathological study of four autopsy cases. Acta Neuropathol.106(4),348–356 (2003).
  MedlineGoogle Scholar
• 42  Dintchov TL, Mehrabian S, Van den BM et al.: Novel PSEN1 mutation in a bulgarian patient with very early-onset Alzheimer’s disease, spastic paraparesis, and extrapyramidal signs. Am. J. Alzheimers Dis. Other Demen.24(5),404–407 (2009).
  MedlineGoogle Scholar
• 43  Piscopo P, Marcon G, Piras MR et al.: A novel PSEN2 mutation associated with a peculiar phenotype. Neurology70(17),1549–1554 (2008).
  Medline CASGoogle Scholar
• 44  Takao M, Ghetti B, Hayakawa I et al.: A novel mutation (G217D) in the presenilin 1 gene (PSEN1) in a Japanese family: presenile dementia and Parkinsonism are associated with cotton wool plaques in the cortex and striatum. Acta Neuropathol.104(2),155–170 (2002).
  Medline CASGoogle Scholar
• 45  Ishikawa A, Piao YS, Miyashita A et al.: A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer’s disease. Ann. Neurol.57(3),429–434 (2005).
  Medline CASGoogle Scholar
• 46  Houlden H, Crook R, Dolan RJ, McLaughlin J, Revesz T, Hardy J: A novel presenilin mutation (M233V) causing very early-onset Alzheimer’s disease with Lewy bodies. Neurosci. Lett.313(1–2),93–95 (2001).
  Medline CASGoogle Scholar
• 47  Lippa CF, Fujiwara H, Mann DM et al.: Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol.153(5),1365–1370 (1998).
  Medline CASGoogle Scholar
• 48  Hamilton RL: Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol.10(3),378–384 (2000).
  Medline CASGoogle Scholar
• 49  Leverenz JB, Fishel MA, Peskind ER et al.: Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch. Neurol.63(3),370–376 (2006).
  MedlineGoogle Scholar
• 50  Cole G, Williams P, Alldryck D, Singharo S: Amyloid plaques in the cerebellum in Alzheimer’s disease. Clin. Neuropathol.8(4),188–191 (1989).
  Medline CASGoogle Scholar
• 51  Larner AJ: The cerebellum in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.8(4),203–209 (1997).
  Medline CASGoogle Scholar
• 52  Lemere CA, Lopera F, Kosik KS et al.: The E280A presenilin 1 Alzheimer mutation produces increased Aβ₄₂ deposition and severe cerebellar pathology. Nat. Med.2(10),1146–1150 (1996).
  Medline CASGoogle Scholar
• 53  Martin JJ, Gheuens J, Bruyland M et al.: Early-onset Alzheimer’s disease in 2 large Belgian families. Neurology41(1),62–68 (1991).
  Medline CASGoogle Scholar
• 54  Haltia M, Viitanen M, Sulkava R et al.: Chromosome 14-encoded Alzheimer’s disease: genetic and clinicopathological description. Ann. Neurol.36(3),362–367 (1994).
  Medline CASGoogle Scholar
• 55  Lampe TH, Bird TD, Nochlin D et al.: Phenotype of chromosome 14-linked familial Alzheimer’s disease in a large kindred. Ann. Neurol.36(3),368–378 (1994).
  Medline CASGoogle Scholar
• 56  Mann DM, Iwatsubo T, Ihara Y et al.: Predominant deposition of amyloid-β₄₂₍₄₃₎ in plaques in cases of Alzheimer’s disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am. J. Pathol.148(4),1257–1266 (1996).
  Medline CASGoogle Scholar
• 57  Mann DM, Jones D, Prinja D, Purkiss MS: The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down’s syndrome and Alzheimer’s disease. Acta Neuropathol.80(3),318–327 (1990).
  Medline CASGoogle Scholar
• 58  Mann DM, Iwatsubo T: Diffuse plaques in the cerebellum and corpus striatum in Down’s syndrome contain amyloid β protein (Aβ) only in the form of Aβ₄₂(43). Neurodegeneration5(2),115–120 (1996).
  Medline CASGoogle Scholar
• 59  Fukutani Y, Cairns NJ, Rossor MN, Lantos PL: Cerebellar pathology in sporadic and familial Alzheimer’s disease including APP 717 (Val-->Ile) mutation cases: a morphometric investigation. J. Neurol. Sci.149(2),177–184 (1997).
  Medline CASGoogle Scholar
• 60  Piccini A, Zanusso G, Borghi R et al.: Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype. Arch. Neurol.64(5),738–745 (2007).
  MedlineGoogle Scholar
• 61  Anheim M, Hannequin D, Boulay C, Martin C, Campion D, Tranchant C: Ataxic variant of Alzheimer’s disease caused by Pro117Ala PSEN1 mutation. J. Neurol. Neurosurg. Psychiatr.78(12),1414–1415 (2007).
  Medline CASGoogle Scholar
• 62  Dermaut B, Kumar-Singh S, De Jonghe C et al.: Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer’s disease due to a novel presenilin 1 mutation. Brain124(Pt 12),2383–2392 (2001).
  Medline CASGoogle Scholar
• 63  Yasuda M, Maeda K, Ikejiri Y, Kawamata T, Kuroda S, Tanaka C: A novel missense mutation in the presenilin-1 gene in a familial Alzheimer’s disease pedigree with abundant amyloid angiopathy. Neurosci. Lett.232(1),29–32 (1997).
  Medline CASGoogle Scholar
• 64  Steiner H, Revesz T, Neumann M et al.: A pathogenic presenilin-1 deletion causes abberrant Aβ₄₂ production in the absence of congophilic amyloid plaques. J. Biol. Chem.276(10),7233–7239 (2001).
  Medline CASGoogle Scholar
• 65  Yasuda M, Maeda S, Kawamata T et al.: Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy. J. Neurol. Neurosurg. Psychiatr.68(2),220–223 (2000).
  Medline CASGoogle Scholar
• 66  Mullan M, Crawford F, Axelman K et al.: A pathogenic mutation for probable Alzheimer’s disease in the APP gene at the N-terminus of β-amyloid. Nat. Genet.1(5),345–347 (1992).
  Medline CASGoogle Scholar
• 67  Van Broeckhoven C, Haan J, Bakker E et al.: Amyloid β protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science248(4959),1120–1122 (1990).
  Medline CASGoogle Scholar
• 68  Hendriks L, van Duijn CM, Cras P et al.: Presenile dementia and cerebral hemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nat. Genet.1(3),218–221 (1992).
  Medline CASGoogle Scholar
• 69  Roks G, Van Harskamp F, De K, I et al.: Presentation of amyloidosis in carriers of the codon 692 mutation in the amyloid precursor protein gene (APP692). Brain123(Pt 10),2130–2140 (2000).
  MedlineGoogle Scholar
• 70  Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM: Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol.49(6),697–705 (2001).
  Medline CASGoogle Scholar
• 71  Basun H, Bogdanovic N, Ingelsson M et al.: Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch. Neurol.65(4),499–505 (2008).
  MedlineGoogle Scholar
• 72  Guyant-Marechal I, Berger E, Laquerriere A et al.: Intrafamilial diversity of phenotype associated with app duplication. Neurology71(23),1925–1926 (2008).
  Medline CASGoogle Scholar
• 73  Kasuga K, Shimohata T, Nishimura A et al.: Identification of independent APP locus duplication in Japanese patients with early-onset Alzheimer disease. J. Neurol. Neurosurg. Psychiatr.80(9),1050–1052 (2009).
  Medline CASGoogle Scholar
• 74  Schott JM, Ridha BH, Crutch SJ et al.: Apolipoprotein e genotype modifies the phenotype of Alzheimer disease. Arch. Neurol.63(1),155–156 (2006).
  MedlineGoogle Scholar
• 75  Harold D, Abraham R, Hollingworth P et al.: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat. Genet.41(10),1088–1093 (2009).
  Medline CASGoogle Scholar
• 76  Lambert JC, Heath S, Even G et al.: Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat. Genet.41(10),1094–1099 (2009).
  Medline CASGoogle Scholar
• 77  Belbin O, Beaumont H, Warden D, Smith AD, Kalsheker N, Morgan K: PSEN1 polymorphisms alter the rate of cognitive decline in sporadic Alzheimer’s disease patients. Neurobiol. Aging30(12),1992–1999 (2009).
  Medline CASGoogle Scholar
• 78  Beck JA, Poulter M, Campbell TA et al.: Somatic and germline mosaicism in sporadic early-onset Alzheimer’s disease. Hum. Mol. Genet.13(12),1219–1224 (2004).▪ Introduces somatic and germline mosaicism as novel disease mechanisms in AD, reporting an individual demonstrating a PSEN1 mutation in DNA extracted from the cerebral cortex, which was not detectable on peripheral blood sequencing.
  Medline CASGoogle Scholar
• 79  Weller RO, Boche D, Nicoll JA: Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’s disease and their potential impact on therapy. Acta Neuropathol.118(1),87–102 (2009).
  Medline CASGoogle Scholar
• 80  Boche D, Zotova E, Weller RO et al.: Consequence of Aβ immunization on the vasculature of human Alzheimer’s disease brain. Brain131(Pt 12),3299–3310 (2008).
  Medline CASGoogle Scholar
• 81  Dillen K, Annaert W: A two decade contribution of molecular cell biology to the centennial of Alzheimer’s disease: are we progressing towards therapy? In: International Review of Cytology (Volume 254). Jeon KW (Ed.). Elsevier, 215–300 (2006).
  Google Scholar
• 101  Alzheimer Disease and Frontotemporal Dementia Mutation Database www.molgen.ua.ac.be/ADMutations
  Google Scholar